ClinicalTrials.gg
RecruitingNCT06876662Updated Mar 2, 2026

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

A Phase 4 interventional study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma, sponsored by Eli Lilly and Company. Recruiting at 36 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
279
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
7th of 23
279 · median 87
Started
2025
with 6 others
Phase 4
3 of 23
3 open now
Primary completion
2030-05
later than 13 of 18 live
Registered
15th of 23
by date
Lead sponsor
5 of 23
Eli Lilly and Company

Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 7th largest by planned enrollment, is one of 7 that started in 2025, is one of 3 in phase 4, reaches primary completion later than 13 of the 18 other live ones, and was the 15th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:

    • receiving study intervention
    • in the short-term follow-up period, or
    • in the long-term follow-up period

Exclusion criteria

Exclusion Criteria:

  • Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
279 participants (estimated)

Study arms

  • Experimental
    JZ01 Pirtobrutinib

    Participants receive pirtobrutinib as defined in the originator study (LOXO-BTK-18001/J2N-OX-JZNA). Pirtobrutinib administered orally.

    Drug: Pirtobrutinib

Interventions

  • Administered orally.

    Also known as: LOXO-305, LY3527727

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with a Grade ≥3 treatment-emergent adverse events (TEAEs)

    Time frame: Time from the Date of the First Dose of Study Intervention (Study Day 1) through 30 Days (+ 7-day window) After the Date of the Last Dose of Study Intervention or The First Date Starting a New Anticancer Therapy, whichever is Earlier

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as the time from enrollment from the originator study until death from any cause

    Time frame: Time from Enrollment from the Originator Study until Death from Any Cause (Up to 93 Months)

07

Study locations

25 of 36 sites recruiting
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136-1002, United States
    Recruiting
    • · Contact954-265-6549
    • Alvaro Alencar · Principal investigator
  • Florida Cancer Specialists
    Sarasota, Florida 34232-6422, United States
    Recruiting
    • · Contact941-377-9993
    • Manish Patel · Principal investigator
  • The Emory Clinic
    Atlanta, Georgia 30322-1013, United States
    Recruiting
    • · Contact404-778-3708
    • Jonathon Cohen · Principal investigator
  • Northwestern University
    Chicago, Illinois 60611-3013, United States
    Recruiting
    • · Contact312-908-5250
    • Shuo Ma · Principal investigator
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02115, United States
    Recruiting
    • · Contact617-632-5847
    • Jennifer Brown · Principal investigator
  • Mayo Clinic- Minnesota
    Rochester, Minnesota 55905, United States
    Recruiting
    • · Contact507-284-2511
    • Yucai Wang · Principal investigator
  • University Of Nebraska Medical Center
    Omaha, Nebraska 69198, United States
    Recruiting
    • · Contact402-559-5166
    • Matthew Lunning · Principal investigator
  • Cayuga Cancer Center
    Ithaca, New York 14850, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Northwell Health
    Lake Success, New York 11042-1118, United States
    Recruiting
    • · Contact516-734-8959
    • Steven Allen · Principal investigator
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
    New York, New York 10065-6007, United States
    Recruiting
    • · Contact646-608-4273
    • Prioty Islam · Principal investigator
  • Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
    New York, New York 10065-6007, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Duke University Medical Center
    Durham, North Carolina 27710-4000, United States
    Recruiting
    • · Contact919-684-8111
    • Matthew McKinney · Principal investigator
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210-1063, United States
    Recruiting
    • · Contact614-293-3196
    • Jennifer Woyach · Principal investigator
  • University of Pennsylvania Hospital
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • · Contact215-662-3933
    • Sunita Nasta · Principal investigator
  • Tennessee Oncology
    Nashville, Tennessee 37203-2659, United States
    Recruiting
    • · Contact615-524-4074
    • Michael Byrne · Principal investigator
  • University of Texas MD Anderson Cancer Center
    Houston, Texas 77030-4000, United States
    Recruiting
    • · Contact713-792-2860
    • Michael Wang · Principal investigator
  • Swedish Cancer Institute
    Seattle, Washington 98104-3588, United States
    Recruiting
    • · Contact908-208-4685
    • Swathi Namburi · Principal investigator
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226-3548, United States
    Recruiting
    • · Contact414-805-4600
    • Nirav Shah · Principal investigator
  • Flinders Medical Centre
    Adelaide, 5042, Australia
    Recruiting
    • · Contact+61882044018
    • Hui-Peng Lee · Principal investigator
  • Peter MacCallum Cancer Centre
    Melbourne, 3000, Australia
    Completed

    Not enrolling at this site — choose another above.

  • Linear Clinical Research
    Victoria, 3000, Australia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • CHU de Nantes - Hotel Dieu
    Nantes, 44093, France
    Recruiting
    • · Contact+33240083271
    • Thomas Gastinne · Principal investigator
  • IRCCS-AOU di Bologna-Policlinico S.Orsola-Malpighi
    Bologna, 40138, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Ospedale San Raffaele
    Milan, 20132, Italy
    Recruiting
    • · Contact+390226434797
    • Paolo Ghia · Principal investigator
  • Nagoya Medical Center
    Aichi-Ken, 4600001, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • National Cancer Center Hospital
    Cho-ku, 104-0045, Japan
    Completed

    Not enrolling at this site — choose another above.

  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tokai University Hospital- Isehara Campus
    Isehara, 259-1193, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Tohoku University Hospital
    Miyagi-Ken, 9808574, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hokkaido University Hospital
    Sapporo, 060-8648, Japan
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Pratia MCM Krakow
    Krakow, 30727, Poland
    Recruiting
    • · Contact+48124003200
    • Wojciech Jurczak · Principal investigator
  • Instytut Hermatologii I Transfuzjologii
    Warsaw, 02-776, Poland
    Recruiting
    • · Contact+48223496334
    • Ewa Lech-Maranda · Principal investigator
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Recruiting
    • · Contact+821071243234
    • Ja Min Byun · Principal investigator
  • St James's University Hospital
    Leeds, LS9 7TF, United Kingdom
    Recruiting
    • · Contact+441132433144
    • Talha Munir · Principal investigator
  • Churchill Hospital
    Oxford, OX3 7LE, United Kingdom
    Recruiting
    • · Contact+447728268414
    • Toby Eyre · Principal investigator
  • Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
    Recruiting
    • · Contact+441752431043
    • David John Lewis · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for May 2030, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2025
First posted
Mar 14, 2025
StartActual
May 20, 2025
Primary completionEst.
May 2030
CompletionEst.
Dec 2032
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06876662
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
May 20, 2025
Primary completion
May 2030 (estimated)
Completion
Dec 2032 (estimated)
Last update
Mar 2, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion